AUTHORS
Lindsay Rein, MD, James K. McCloskey, MD2, Joseph Scandura, MD, PhD3, Firas El Chaer, M.D.4, Andrew Srisuwananukorn, MD5, Junichiro Yuda, MD, PhD6, Kazuya Shimoda, MD, PhD7, Alessandro Lucchesi, MD, PhD8, Ashwin Kishtagari, MBBS, MSCI9, Noboru Asada, MD, PhD10, Tamanna Haque, MD11, Vikas Gupta, MD FRCP, FRCPath12, Raajit K. Rampal, MD, PhD13, Marcello Rotta14, Claire Harrison, DM15, Timothy Devos, MD, PhD16, Gabriela Soriano Hobbs, MD17, Vincent Ribrag, MD18, Michiko Ichii, MD, PhD19, John O. Mascarenhas, MD20, Florian H. Heidel IV, MD21, Francesco Passamonti, MD22, Jose Torregrosa, MD23, Stefan Wickenhauser, MD24, Giulia Benevolo, MD25, Alessandra Iurlo, MD26, Noriko Fukuhara, MD27, Jean-Jacques Kiladjian, MD, PhD28, Srinivas Tantravahi, MD29, Idoroenyi Amanam, MD30, Naveen Premnath, MD31, Ronald Hoffman, MD32, Ruben Mesa, MD33, Ciro R. Rinaldi, MD, PhD34, Marina Kremyanskaya, MD, PhD35, Joshua Casan, MD, PhD36, Moshe Talpaz, MD37, Anna Halpern, MD38, Pankit Vachhani, MD39, Francoise Boyer40, Anthony Michael Hunter, MD41, Masataka Seki42, Karen Ansaldo, PharmD43, Vincent Loksa, PharmD44, Jinny Lee, PhD45, Zhonggai Li, PhD46, Sujan Kabir, MD47, Prithviraj Bose, MD48
AFFILIATIONS
1 Duke University Medical Center, Durham, North Carolina, United States
2 John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, United States
3 Weill Cornell Medicine, New York, New York, United States
4 Herbert Wertheim Cancer Institute, Baptist Health, Miami, Florida, United States
5 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
6 National Cancer Center Hospital East, Kashiwa, Japan
7 University of Miyazaki, Miyazaki, Japan
8 IRCCS Istituto Romagnolo per lo Studio e la Cura dei Tumori (IRST) “DinoAmadori”, Meldola, Italy
9 Vanderbilt University Medical Center, Nashville, Tennessee, United States
10 Okayama University Hospital, Okayama, Japan
11 Memorial Sloan Kettering Cancer Center, New York, New York, United States
12 Princess Margaret Cancer Centre, Toronto, Canada
13 Memorial Sloan Kettering Cancer Center, New York, New York, United States
14 Colorado Blood Cancer Institute, Denver, Colorado, United States
15 Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
16 University Hospitals Leuven and Department of Microbiology and Immunology, Laboratory of Molecular Immunology (Rega Institute), Leuven, Belgium
17 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
18 Institut Gustave Roussy, Villejuif, France
19 The University of Osaka Graduate School of Medicine, Suita, Japan
20 Icahn School of Medicine at Mount Sinai, New York, New York, United States
21 Hannover Medical School (MHH), Hematology, Hemostasis, Oncology and Cell Therapy, Hannover, Germany
22 Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
23 University Hospital of Poitiers, Poitiers, France
24 CHU de Nîmes, Nîmes, France
25 Azienda Ospedaliero-Universitaria, Turin, Italy
26 Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
27 Tohoku University Hospital, Sendai, Japan
28 Hopital Saint-Louis, Paris, France
29 Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
30 City of Hope, Duarte, California, United States
31 University of Minnesota, Minneapolis, Minnesota, United States
32 Icahn School of Medicine at Mount Sinai, New York, New York, United States
33 Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States
34 United Lincolnshire Hospitals NHS Trust, Lincoln, United Kingdom
35 Icahn School of Medicine at Mount Sinai, New York, New York, United States
36 Peter MacCallum Cancer Centre, Melbourne, Australia
37 University of Michigan, Ann Arbor, Michigan, United States
38 Fred Hutchinson Cancer Center and University of Washington, Seattle, Washington, United States
39 University of Alabama at Birmingham, Birmingham, Alabama, United States
40 Angers University Hospital, Angers, France
41 Emory University School of Medicine, Atlanta, Georgia, United States
42 Sumitomo Pharma America, Inc., Marlborough, United States
43 Sumitomo Pharma America, Inc., Marlborough, United States
44 Sumitomo Pharma America, Inc., Marlborough, United States
45 Sumitomo Pharma America, Inc., Marlborough, United States
46 Sumitomo Pharma America, Inc., Marlborough, United States
47 Sumitomo Pharma America, Inc., Marlborough, United States
48 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Background: PIM1 is downstream of JAK/STAT signalling leading to its upregulation in myelofibrosis (MF). Additionally, PIM1 expression can be upregulated by NF-kB and ERG, which functions as JAK-independent compensatory pathways that drive MF pathogenesis. Dual inhibition of JAK and PIM1 may provide more comprehensive suppression of these combined disease-relevant pathways. Momelotinib (MMB), a JAK/ACVR1 inhibitor, showed ≥50% reduction in total symptom score (TSS50) of 25%, ≥35% spleen volume reduction (SVR35) of 22%, and anemia improvement in patients (pts) with MF previously treated with a JAK inhibitor. Nuvisertib (nuvi), an oral investigational selective PIM1 inhibitor with added ACVR1 inhibition, was well tolerated as monotherapy and showed symptoms and spleen volume reductions as well as hemoglobin (Hgb) and platelet (PLT) responses correlating with cytokine modulation in pts with relapsed/refractory (R/R) MF. In a preclinical study, combined administration of nuvi + MMB showed additive reduction of hepcidin mRNA which further supports nuvi as a complementary combination partner with MMB. Here, we present preliminary data of nuvi + MMB combination in pts with R/R MF.
Methods: The global Phase 1/2 study (NCT04176198, Arm 3) aims to identify the RP2D of nuvi + MMB in pts with R/R MF and anemia and to assess safety, clinical activity, and PK/PD. Key eligibility criteria include primary or secondary MF previously treated with a JAK inhibitor (JAKi, prior MMB was not allowed), DIPSS intermediate or high-risk, Hgb <10 g/dL, PLT ≥50 x 109/L, splenomegaly (≥450 cm3), and ≥2 symptoms with each score ≥3 or TSS of ≥10 per MFSAF v4.
Results: As of 18 June 2026, total 64 pts were enrolled in 4 dose levels of nuvi at 240 (n=20), 360 (n=20), 480 (n=20), or 720 (n=4) mg BID + MMB 200 mg QD in the Phase 1 dose escalation part. At baseline, median (range) age 71 years (56, 86); TSS 23 (8, 57); spleen volume 1570 cm3 (456, 5428); Hgb 8.8 g/dL (4.5, 10.9; 56% pts required transfusion); and PLT 147 x 109/L (50, 661; 27% pts with PLT <100 x 109/L). All pts received prior JAKi treatment; median duration of prior JAKi was 28 months (1, 154; 67% pts received prior JAKi for ≥12 months), and 45% pts had high molecular risk mutations. Median treatment duration was 19 weeks (1, 64), and 78% (50/64) pts remained on treatment. No DLTs occurred. Combination treatment-related adverse events (TRAEs) occurring in ≥20% pts were diarrhea, nausea, and thrombocytopenia (TCP). Grade 3/4 TRAE occurring in >2 pts included TCP (n=12) and anemia (n=5); no Grade 5 AEs occurred. Dose modifications due to TRAEs occurred in 34% (22/64) pts. Mean Hgb and PLT remained stable throughout the 24-week treatment. Pts who completed ≥24 weeks of treatment or discontinued treatment earlier due to TRAE or progressive disease were considered Week 24 (WK24) efficacy evaluable (N=29 for spleen and anemia and N=27 for symptom assessment [MFSAF data missing for 2 pts]). Early and sustained symptoms, spleen and anemia responses were observed across all dose levels evaluated. TSS reduction was observed in 78% (21/27) pts; TSS50 at WK24 was 41% (11/27) and best TSS50 at any time was 52% (14/27). Absolute reduction was observed in all 7 symptoms, including 44% reduction in fatigue score at WK24 (mean baseline and WK24 fatigue scores: 5.6 and 3.1, respectively). SVR was achieved in 69% (20/29) pts; SVR35 at WK24 was 45% (13/29) and best SVR35 at any time was 48% (14/29). Anemia response per the IWG ELN2024 was observed in 52% (15/29) pts at WK24 including 8 major and 7 minor responses. A decrease in the mean hepcidin levels was observed from Week 12 and hepcidin levels remained reduced thereafter. At WK24, 22% (6/27) pts achieved all three responses (TSS50, SVR35 and anemia), and 37% (10/27) pts achieved at least two responses. Increased adiponectin and EPO and decreased IL-18 and MIP-1β were also observed and associated with TSS and/or spleen responses. Dose optimization is ongoing.
Conclusions: In this ongoing global Phase 1 dose escalation part of the study in pts with R/R MF and anemia, nuvi + MMB appeared well tolerated in the dose levels evaluated. Preliminary nuvi + MMB data showed promising clinical activity including symptoms and spleen responses, anemia improvement and cytokine modulation. Emerging clinical data supports Phase 3 development of nuvi + MMB combination for pts with MF and anemia.
DISCLOSURES
Lindsay Rein, MD: Cogent Biosciences - Honoraria; Protagonist - Honoraria; Sumitomo - Honoraria; Merck - Honoraria; Blueprints Medicine - Honoraria; Sobi - Honoraria; Takeda - Honoraria; Incyte Corporation - Honoraria; Pharmaessentia - Honoraria; Novartis - Honoraria; Sumitomo - Research Funding; Incyte Corporation - Research Funding; Merck - Research Funding; Novartis - Research Funding; Telios - Research Funding; Blueprints Medicine - Research Funding; Pharmaessentia - Research Funding; DISC Medicine - Research Funding; Kartos Therapeutics - Research Funding; Kumquat Biosciences - Research Funding; Geron Corporation - Research Funding; Protagonist - Research Funding; Karyopharm - Research Funding; Cogent Biosciences - Research Funding; Silence Therapeutics - Research Funding; Sumitomo - Consultancy (Includes expert testimony); Sobi - Consultancy (Includes expert testimony); Cogent Biosciences - Consultancy (Includes expert testimony)